Is Psilocybin’s Next Frontier Metabolic Health?

Good morning and welcome back to the Drop In! We're kicking things off with a story about how psilocybin could become a therapy to treat obesity-related diseases.

This study caught our eye because it marks a turning point in the narrative around psychedelics. Most prior research has focused on mental health applications. But this preclinical study examines psilocybin as a medicine for metabolic health, raising intriguing questions about how the compound affects the body, particularly the liver. You can read the story immediately below!

If you keep scrolling, you’ll find guides on how to trip sit, a story on “trauma” being a catch-all term, medicine workers getting arrested, and so much more.

Happy Snow Moon 🌕,
Mary Carreón
Editor-in-Chief

Together With MV. Health

Arouse the whole vulva with Legato, the vibrating ring. 

Want to take your intimacy to new heights of sensual connection?   

Legato is a multi-award-winning vibrator ring that awakens every inch of her pleasure zones. It’s designed to stimulate the entire vulva—clitoris, labia, and everything in between. With 4 motors and an adjustable shape, it ignites every nerve ending, magnifying sensations everywhere she could possibly want them.   

With a spacious opening for a partner (or another toy) and 16 intensity levels, it gives plenty for both partners to explore. It’s even gained a hot reputation among OB/GYN doctors for heightening arousal and supporting natural lubrication, making it perfect for postpartum and menopause (it’s even FDA-registered).  

Right now, you can save 50% during their Valentine’s Day Sale.  Just click the link below👇 

Take your intimacy to new heights with Legato.

Microdosing Psilocybin May Treat Obesity-Related Diseases, New Study Says

Researchers found that sub-perceptual doses of psilocybin improved metabolic markers linked to obesity, diabetes, and fatty liver disease, without affecting appetite or the nervous system.

A new preclinical study by a conglomerate of Italian universities suggests that psilocybin may offer metabolic benefits at sub-perceptual doses, pointing to a potential new therapy for obesity-related diseases.

The research, published in the journal Pharmacological Research, found that regular administration of very low doses of psilocybin improved metabolic health in mice with obesity, type 2 diabetes, and metabolic dysfunction–associated steatotic liver disease, or MASLD, a condition commonly referred to as Fatty Liver Disease. The study was led by researchers at the University of Padua and the University of Milan and involved institutional collaborators across Europe and the United States.

In the study, mice that were fed a high-fat, high-fructose diet received psilocybin at a dose of 0.05 milligrams per kilogram for 12 weeks. Over that time, researchers observed reduced weight gain, improved insulin sensitivity, normalized blood glucose levels, and a regression of fatty liver disease. What’s perhaps most notable about these findings is that the changes occurred without reducing food intake and without detectable effects on the central nervous system.

Through molecular and tissue-level analyses, the researchers found that consuming small doses of psilocybin helped restore the liver’s chemistry, allowing its metabolism to function closer to normal again. Psilocybin also reduced the accumulation of harmful lipid species, restored insulin signaling pathways, and produced visible improvements in liver structure and key metabolic markers.

“These data challenge the idea that the therapeutic potential of psilocybin is necessarily linked to the psychedelic experience,” said Sara De Martin, corresponding author of the study and a professor in the Department of Pharmaceutical Sciences at the University of Padua. “At [consistent] low doses, psilocybin acts as a peripheral modulator of metabolism, particularly at the liver level, through a distinct serotonergic pathway.”

Further analysis showed that these metabolic benefits weren’t tied to the serotonin receptor, known as 5-HT2A, that produces the psychedelic experience associated with psilocybin mushrooms. Instead, the benefits came from psilocybin blocking a specific serotonin receptor in the liver, known as 5-HT2B, which researchers confirmed using experiments on human liver cells.

But the findings also extended beyond the liver. Psilocybin-treated mice demonstrated improved muscle strength and function, alongside restored sensitivity to leptin, a hormone involved in regulating energy balance and muscle metabolism. Additionally, pancreatic tissue analysis showed recovery of insulin-producing beta cells that were damaged by the high-fat diet.

“These studies, conducted in an experimental mouse model, suggest that psilocybin could represent a new treatment for MASLD, type 2 diabetes, and obesity in humans,” said Franco Folli, corresponding author and professor at the Department of Health Sciences at the University of Milan.

While these findings are limited to animal models, the implications suggest that psilocybin may have significant applications beyond mental health. The physiological benefits of psychedelics have yet to be explored scientifically at the rate and depth of their impacts on psychological wellbeing. This study, thus, marks a deviation from the current narrative focusing on mental health and opens the door for greater inquiry into a more holistic understanding and application of these substances.

Psychedelic Policy Takes Center Stage on Capitol Hill Amid Growing Controversy

As bipartisan momentum builds to expand access to psychedelic-assisted therapies for U.S. veterans, a growing mix of political scandals, ethical concerns, and competing legislative approaches is complicating the path forward in Washington.

This week, journalist Jack Gorsline digs into how two major federal bills — one aimed at integrating psychedelic treatments into the VA and another focused on expanding patient access through Right to Try — are reshaping the policy landscape. Along the way, he examines how controversies tied to the “ibogaine lobby” and calls for congressional oversight are testing the movement’s credibility at a pivotal moment.

Update your subscription here to get the full story in your inbox on Friday!

DoubleBlind Digs

ATTEND: Michael Pollan has announced a tour to promote his latest book, “A World Appears: A Journey Into Consciousness.” Check out his tour dates here.

CONVOS: Join Chacruna for a critical conversation examining U.S. intervention in Venezuela, the enduring Drug War, and what military imperialism, narco-politics, and psychedelic expansion mean for veterans, Latin America, and accountability in today’s psychedelic movement. Register here.

PETS: This month’s Psychedelic Professionals Meet takes a closer look at something often overlooked: how altered states can impact the animals we live with—and what responsibility, respect, and care look like in our psychedelic lives. Join Casara Andre and Dori Lewis for a conversation on consent, animal safety, and the ripple effects of psychedelic experiences beyond the self. Learn more and attend here.

Together With MV. Health

Best Valentine’s Day Gift Ever? Psychedelic Orgasms

Celebrate this Valentine’s Day with a gift you’ll both remember: mind-blowing orgasms that leave you in a breathless state of ecstasy, riding a days-long afterglow of awe-inspired gratitude for the glory of the universe and existence itself. 

Try MV.Health’s Tenuto 2 vibrator.   

It’s a vibrator designed for both partners. It gives you both more powerful orgasms, bringing you both to new heights of sexual, soul-satisfying pleasure you didn’t even know was possible.  

 (Yes, it even helps with sensitive sexual issues like ED, orgasmic dysfunction, and boredom.) 

 Right now MV.Health is running a Valentine’s Day Sale. It’s HUGE. You can save 50% during their Valentine’s Day Sale. Just click the link below 👇 

Make your orgasms more psychedelic with MV.Health.